Clinical phenotype of ASD-associated DYRK1A haploinsufficiency

Rachel K. Earl¹, Tychele N. Turner², Heather C. Mefford³, Caitlin M. Hudac¹, Jennifer Gerds³, Evan E. Eichler²,4 and Raphael A. Bernier¹,5*

Abstract

Background: DYRK1A is a gene recurrently disrupted in 0.1–0.5% of the ASD population. A growing number of case reports with DYRK1A haploinsufficiency exhibit common phenotypic features including microcephaly, intellectual disability, speech delay, and facial dysmorphisms.

Methods: Phenotypic information from previously published DYRK1A cases (n = 51) and participants in an ongoing study at the University of Washington (UW, n = 10) were compiled. Frequencies of recurrent phenotypic features in this population were compared to features observed in a large sample with idiopathic ASD from the Simons Simplex Collection (n = 1981). UW DYRK1A cases were further characterized quantitatively and compared to a randomly subsampled set of idiopathic ASD cases matched on age and gender (n = 10) and to cases with an ASD-associated disruptive mutation to CHD8 (n = 12). Contribution of familial genetic background to clinical heterogeneity was assessed by comparing head circumference, IQ, and ASD-related symptoms of UW DYRK1A cases to their unaffected parents.

Results: DYRK1A haploinsufficiency results in a common phenotypic profile including intellectual disability, speech and motor difficulties, microcephaly, feeding difficulties, and vision abnormalities. Eighty-nine percent of DYRK1A cases ascertained for ASD presented with a constellation of five or more of these symptoms. When compared quantitatively, DYRK1A cases presented with significantly lower IQ and adaptive functioning compared to idiopathic cases and significantly smaller head size compared to both idiopathic and CHD8 cases. Phenotypic variability in parental head circumference, IQ, and ASD-related symptoms corresponded to observed variability in affected child phenotype.

Conclusions: Results confirm a core clinical phenotype for DYRK1A disruptions, with a combination of features that is distinct from idiopathic ASD. Cases with DYRK1A mutations are also distinguishable from disruptive mutations to CHD8 by head size. Measurable, quantitative characterization of DYRK1A haploinsufficiency illuminates clinical variability, which may be, in part, due to familial genetic background.

Keywords: Autism, DYRK1A, Genetic syndrome, Genetically defined subtype, Disruptive mutation, Clinical phenotype

Background

Autism spectrum disorder (ASD) is characterized by tremendous clinical variability and causal heterogeneity. Historical efforts to behaviorally subtype ASD have been largely unsuccessful due to lack of meaningful treatment implications by subtype and inadequate consensus regarding clinical phenotype [1, 2]. Recent efforts have targeted the genetic causes of ASD to explore biologically defined subtypes [3, 4]. Advances in genetic sequencing technology have improved our ability to identify disease-causing mutations [5]. Chromosomal abnormalities, copy number variants (CNVs), and disruptive single nucleotide variants (SNVs), including nonsense, frameshift, and splice site mutations, have been associated with increased risk of ASD [6–9]. Most recently, work relating ASD risk to de novo disruptive SNVs suggests these single point mutations account for approximately 10% of ASD cases [6, 8]. These discoveries have prompted a shift in ASD research; instead of using extensive phenotyping prior to sequencing ASD populations, researchers have begun by identifying genes of
interest in affected individuals and then exploring phenotype in specific gene cohorts [10].

The application of this genetics-first approach to subtyping ASD has successfully identified similar medical, behavioral, and dysmorphic features shared by individuals with disruptive variants in high-confidence ASD risk genes, such as \( CHD8 \), \( ADNP \), \( SCN2A \), and \( DYRK1A \) (e.g., [11–13]). Dual-specificity tyrosine phosphorylation-regulated kinase 1A, or \( DYRK1A \), is a highly conserved gene in the Down syndrome critical region of chromosome 21 [6, 14], and appears to play a major role in brain development, specifically neurogenesis, neural plasticity, and cellular death [15]. \( DYRK1A \) haploinsufficiency was initially identified for its role in intellectual disability, which is clinically defined as childhood onset of significant cognitive and adaptive impairment [16]. Recurrent disruptions to \( DYRK1A \) have been found in as many as 0.5% of cases with ASD [14, 17]. In \( Drosophila \) models, truncating mutations to \( DYRK1A \) (\( Drosophila \) ortholog termed the Minibrain (\( Mnb \) gene) result in microcephaly, including intact but smaller brain structures [18]. \( Dyrk1a \)-null mouse models (\( +/- \)) displayed growth deficiencies resulting in mid-gestational death [19]. Mice heterozygous for \( Dyrk1a \) (\( +/- \)) survived to adulthood but presented with reduced growth, developmental delays, motor and learning difficulties, and atypical behaviors, including anxiety [19, 20]. A consistent clinical phenotype appears in humans. Reported cases to date have exhibited microcephaly and intellectual disability; other features, including seizures, speech and motor delays, feeding difficulties, and distinct facial dysmorphology, have been noted as well [13, 15, 21–24].

Studies relying on medical record review have reported ASD diagnoses in up to 40% of cases with \( DYRK1A \) mutations, but many remaining cases have features consistent with ASD, such as stereotypies, reduced eye contact, and social anxiety [15, 21]. Few studies have conducted diagnostic evaluations of ASD and ASD-related symptoms as part of a clinical phenotyping battery. Diagnostic rates may be as high as 88% when ASD is directly evaluated as part of the study assessment process [13].

Literature on \( DYRK1A \) haploinsufficiency supports its association with ASD risk and suggests a complex phenotype that includes distinct dysmorphology as well as cognitive, neurological, and medical impairments. However, studies to date have only reported categorical descriptions of phenotype, which note the presence or absence of a common phenotype, such as ASD or no ASD. Quantitative assessments of ASD-related features in large cohorts and in relation to other ASD cohorts have not been examined. While previously published reports have noted an emerging phenotypic profile, variability in clinical presentation remains. Measurable data on medical, developmental, and behavioral characteristics are needed to better understand small variations in phenotype between individuals. Furthermore, varied clinical presentations of individuals with \( DYRK1A \) mutations have yet to be examined in the context of their familial phenotypic profile as a measure of remaining genetic background. This approach has been applied to other developmental disorders and to CNVs associated with ASD, but has yet to be applied to disruptive SNVs associated with ASD [25–28].

The aim of the proposed study was to examine a large cohort of cases with \( DYRK1A \) mutations, provide a summary of phenotype, and compare recurrent medical and behavioral features to (1) large idiopathic ASD samples and (2) a cohort with disruptive mutations to a different ASD-associated gene, \( CHD8 \). Alongside \( DYRK1A \), \( CHD8 \) is one of the most recurrent genes with disruptive SNVs implicated in ASD and provides a comparison group ascertained in the same way as the cases with \( DYRK1A \) mutations in this sample [6, 8]. Detection of phenotypic differences between these two groups could inform understanding of different biological profiles of ASD and illuminate key features unique to each disrupted gene. This study also explored the contribution of genetic background to phenotypic variability among individuals with disruptive \( DYRK1A \) mutations.

**Methods**

**Participants**

**DYRK1A sample**

Participants included 42 individuals with de novo, disruptive, pathogenic SNVs (nonsense, splice site, frameshift, and missense mutations) at the \( DYRK1A \) gene. (Fig. 1; see Additional files 1 and 2 for full variant information). The sample includes 10 individuals assessed as part of an ongoing study at the University of Washington (UW), including 7 new cases identified through clinical genetic testing and 3 previously published cases recruited from the Simons Simplex Collection (see below). In addition to the 3 previously published cases studied at UW, 32 other previously published cases with disruptive SNVs were included in the sample. All subjects were identified via clinical exome sequencing, or exome or targeted sequencing of research cohorts ascertained for a diagnosis of ASD or ID.

Those seen at UW (UW-SNV group; \( n = 9 \) de novo and \( n = 1 \) non-maternal; see Table 1 for variant information [29]) completed standardized behavioral measures and medical evaluations by clinicians naive to gene group membership as part of a study evaluating individuals ages four and older with ASD-associated, disruptive mutations. Biological parents of the participants were also characterized.

Thirty-two previously published cases of \( DYRK1A \) disruptive SNVs (Pub-SNV group) included 31 de novo
cases and 1 non-maternal case [13, 15, 21, 22, 30–32] with available medical history, physical features, and diagnoses.

Additionally, the phenotype of 19 previously published cases of de novo *DYRK1A* chromosomal rearrangements (Pub-CHR group), including microdeletions and translocations, was described and compared to those with disruptive SNVs [21, 24, 33–39]. See Table 2 for participant characteristics for the 61 total *DYRK1A* sample participants.

**Comparison samples**
Secondary data from an idiopathic subset of the Simons Simplex Collection (SSC), a large sample ascertained for ASD, were compared to the *DYRK1A* sample. The SSC was a cohort of 2446 simplex families including a single proband with ASD age 4–18, unaffected biological parents, and any unaffected siblings [40]. Probands were included in the idiopathic subset (*n* = 1981) if they had no known disruptive SNVs or deleterious CNVs, as determined by sequencing efforts by Sanders and colleagues.

---

**Fig. 1** Summary of *DYRK1A* gene variants. Schematic depicting the locations of disruptive variants (truncating, missense, and splice site mutations), copy number variations, and chromosomal rearrangements affecting *DYRK1A*. The ideogram of human chromosome 21 and isoform NM101395.2 coding sequence was obtained from the UCSC genome browser [54]. a NM101395.2 coding sequence with eight reported splice site mutations (presented in HGVS cDNA notation). Mutations below the sequence are UW-SNV participants, above are Pub-SNV mutation cases. b The *DYRK1A* protein (NP_567824.1) with truncating (red) and missense (blue) mutations (presented in HGVS notation). Mutations below the protein are UW-SNV cases, above are Pub-SNV mutation cases. c Copy number deletions and chromosomal rearrangements, including six deletions of entire genes, four partial deletions, five mosaic deletions, and four translocations/inversions (lightning bolt).
in 2015, and not based on any phenotypic or behavioral profile [8]. In order to account for high rates of ID seen in the DYRK1A haploinsufficiency, a subset of the idiopathic group with full-scale IQ below 70 (n=487) served as an additional comparison group. Also, a randomly selected age- and gender-matched subset (n=10) of the full idiopathic sample was compared to the subset of DYRK1A cases assessed qualitatively at the UW. As part of the SSC, probands were assessed on measures of neurocognitive functioning, social communication behaviors, motor skills, physical features (e.g., head circumference), and medical history (measures described below).

Twelve individuals with disruptive SNVs at a different high-confidence ASD risk gene, CHD8 (chromodomain helicase-DNA-binding protein 8), participating in the same UW characterization study and assessed by clinicians naïve to implicated gene disruption, served as a comparison cohort matched on ascertainment approach.

### Measures

**Categorical assessment of diagnostic history and developmental characteristics**

Psychiatric and medical history, developmental milestones, and physiological characteristics were gathered from Pub-SNV and Pub-CHR cases. In addition to published data, supplemental case reports detailing medical history and developmental trajectory were reviewed when available.

For UW-SNV study participants, a structured caregiver interview, adapted from the SSC, was administered to gather information about developmental, psychiatric, and medical history. When caregiver-endorsed diagnoses required additional clarification, medical records were reviewed for confirmation. Using all available information, psychiatric diagnoses were either confirmed or newly diagnosed by a licensed clinical psychologist using the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) [16]. For research purposes, subjects were given an ASD diagnosis based on clinician observation and parent interview using standardized instruments (gold-standard assessment tools described below). A diagnosis of intellectual disability was given when a subject displayed childhood onset of deficits in both cognitive and adaptive functioning. When subjects were under the age of 5 and had failed to reach cognitive developmental milestones at the time of assessment, a diagnosis of Global Developmental Delay was given. A physical and dysmorphology exam was conducted by a licensed medical geneticist.

### Table 1 DYRK1A variant information for UW-SNV mutation patients

| Patient | Position | Type of mutation | cDNA | Protein | Inheritance |
|---------|----------|------------------|------|---------|-------------|
| 1       | 21:38865466 | Splice site      | c.1098+1G>A | –       | De novo     |
| 2       | 21:38845116 | Frameshift       | c.143_144delTA | p.Ile48Lysfs*2 | De novo     |
| 3       | 21:38877833 | Frameshift       | c.1491delC   | p.Ala489Profs*61 | De novo     |
| 4       | 21:38868533 | Frameshift       | c.1217_1220delAGAA | p.Lys406Argfs*44 | De novo     |
| 5       | 21:38862575 | Nonsense         | c.763C>T    | p.Arg255*  | De novo     |
| 6       | 21:38877746 | Frameshift       | c.1401delAinsGG | p.Ile468Aspfs*17 | De novo     |
| 7       | 21:38853064 | Frameshift       | c.452dupA   | p.Asn151Lysfs*12 | Not maternal |
| 8       | 21:38862695 | Missense         | c.883C>T    | p.Leu295Phe | De novo     |
| 9       | 21:38862463 | Splice site      | c.665-8_665-3delTCTTTC | – | De novo     |
| 10      | 21:38877590 | Frameshift       | c.1248delA  | p.Lys416Asnfs*35 | De novo     |

**Participants** for PW-SNV patients using NCBI reference sequence for DYRK1A isoform NM_101395.2, GRCh37 (hg19) build version (Ensembl id: ENST00000338785). This isoform was selected because it was the highest expressing isoform in human tissues in the GTEx database (https://gtexportal.org/home/ gene/DYRK1A) [53]. Patients 1–3 were first identified through the Simons Simplex Collection, patients 4–10 underwent clinical genetic testing prior to research participation. cDNA and protein (NP_567824.1) annotation follows HGVS guidelines.
Quantitative assessment of *DYRK1A* UW-SNV (*n* = 10) and *CHD8* (*n* = 12)

**Head circumference**
Occipital frontal head circumference was measured and standardized values calculated using a normative population reference [41].

**Cognitive functioning**
Full-scale IQ was assessed in probands and unaffected parents. Probands ages 4 years, 0 months to 17 years, 11 months were administered the *Differential Abilities Scales, 2nd Edition* [42]. Probands 18 and older, as well as unaffected parents, were administered the Wechsler Abbreviated Scales of Intelligence [43]. For all assessments, IQ scores were generated using deviation (standard; mean = 100, SD = 15) or ratio scores (mental age equivalent/chronological age × 100). Ratio scores were derived using age equivalence values if standard scores were not possible to calculate due to subject’s level of functioning.

**Adaptive functioning**
Caregivers were administered the *Vineland Adaptive Behavior Scales, 2nd edition* (VABS-2) to measure adaptive functioning across communication, daily living skills, and social domains [44].

**ASD-specific assessment**
Research-reliable clinicians administered the appropriate module of the *Autism Diagnostic Observation Schedule, 2nd Edition* (ADOS-2; [45, 46]) and *Autism Diagnostic Interview-Revised* (ADI-R; [47]). ADOS calibrated severity scores, and items regarding age of first words and age of first steps from the ADI-R were used in analyses. The total T score from the Social Responsiveness Scale (SRS-2; [48]) was used to quantify ASD-associated symptoms in all UW-SNV family members.

**Analytic approach**

**Categorical variables**
Fisher’s exact tests were used to compare frequencies of features commonly found for *DYRK1A* mutations across disruptive SNV (Pub-SNV and UW-SNV) and chromosomal rearrangement (Pub-CHR) groups. These features included intellectual disability, speech delay (defined as first words after 24 months of age), motor deficits (e.g., delayed walking, poor coordination, abnormal gait), ASD-related deficits (e.g., ASD diagnosis, stereotypic behaviors, anxious behaviors), feeding difficulties, seizures, vision abnormalities, and microcephaly. The frequency of most common features (defined as present in 75% or more cases) was compared across *DYRK1A* and idiopathic ASD groups (total idiopathic sample and subset with IQ below 70). Only characteristics specifically noted in case reports were included in analyses; if a phenotypic characteristic was not reported, it was treated as missing for that individual. Total frequencies reflect cases with a reported presence or absence of a given characteristic.

**Quantitative variables**
UW-SNV *DYRK1A* participants were compared to (1) a randomly subsampled age and gender-matched subset of the SSC idiopathic sample and (2) a cohort with disruptive *CHD8* mutations on domains of functioning assessed quantitatively, including head circumference, IQ, adaptive functioning, ASD severity (ADOS calibrated severity score), age of first words (ADI-R), and age of first independent steps (ADI-R). Independent sample *t* tests were used to compare the *DYRK1A*, idiopathic, and *CHD8* groups, using the Bonferroni adjustment for multiple comparisons (*p* < 0.002).

Nonparametric Wilcoxon signed rank tests were used to compare parental and proband phenotype for UW-SNV participants in head circumference, IQ, and ASD symptoms (SRS). Gene “effect size,” measured as the difference between parental and proband phenotype, was calculated as follows:

\[
\text{Effect size} = \frac{\text{Proband mean} - \text{Unaffected biparental mean}}{\text{Unaffected biparental standard deviation}}
\]

When both maternal and paternal data were available, biparental means were calculated as the average of maternal and paternal scores. If only one parent’s data was available, that parent’s score was used instead of a biparental mean.

**Results**

**Clinical phenotype of *DYRK1A***
There were no significant differences between disruptive SNV (Pub-SNV and UW-SNV) and chromosomal rearrangement (Pub-CHR) groups on frequency of phenotypic characteristics (Table 3). Language delay was noted for 61/61 (100%); 21 individuals were nonverbal at the time of their evaluation. Intellectual disability and/or Global Developmental Delay (depending on age) were reported in 60/61 (98%) cases. The presence of motor difficulties, including delayed walking, abnormal gait, and poor coordination, was noted for 52/53 (98%). A common abnormal gait was observed across UW-SNV participants, specifically a lilting gait with a forward lean to the upper body, arms bent and held tight against the body, and hands splayed. Feeding difficulties in infancy, including poor suck, were observed in 51/54 (94%) of those with reports of feeding abilities in early development. Microcephaly, defined as head circumference two or more standard deviations below the mean for age, either primary (present throughout development) or
acquired at a later age, was reported in 58/61 cases (95%). Vision abnormalities were identified in 34/42 (81%) cases, including impairments such as strabismus, astigmatism, optic nerve dysfunction, and corneal clouding. Febrile and non-febrile seizures were reported in 42/58 cases (72%).

Diagnoses of ASD were reported in 18/42 cases (43%), suggesting elevated risk well above the general population percentage of 1.5% [49]. The frequency increased to 42/61 cases (69%) when broadening the criteria to include ASD-related behaviors without a formal diagnosis, such as stereotypic behaviors (e.g., complex motor mannerisms, repetitive and self-stimulatory behaviors), limited eye contact (reported in those without known severe vision impairments), inappropriate laughter, and limited social engagement. Anxious behaviors were reported in 12/44 cases (27%), and hyperactivity was reported in 14/43 cases (33%). Seven of the ten UW-SNV cases were confirmed to have ASD; three who did not meet diagnostic criteria presented with notable stereotypies and socially anxious behaviors.

Co-occurrence of the seven most common phenotypic features (reported in 75% or more of cases) was evaluated: microcephaly, intellectual impairment, speech delay, motor difficulties, feeding difficulties, vision abnormalities, and ASD. Fifty-two percent of the total DYRK1A sample (32/61) possessed six or more features. Sixty-nine percent (42/61) presented with six or more features when the ASD category was broadened to include other behavioral difficulties, including stereotypic, anxious, and hyperactive behaviors.

Facial dysmorphisms were reported in 50/51 (98%) previously published cases (excluding UW-SNV cases who were previously published, n = 3). Similar dysmorphic facial features were observed in eight UW-SNV cases who participated in a standardized medical exam (five new cases, three previously published), including deep-set eyes with a hooded appearance, slightly upslanting palpebral fissures, bitemporal narrowing, prominent brow with high anterior hairline, tubular-shaped nose, prominent nasal bridge, retrognathic jaw, and small chin (Fig. 2a). Additionally, prominent, low-set, or malformed ears were also reported across cases; 4/8 UW-SNV cases presented with thick, overfolded ear helices (Fig. 2b). Foot anomalies were also noted across patients, including toe syndactyly (webbing of the toes), arachnodactyly, crooked toes, and proximal placement of the first toe (Fig. 2c). Observed commonalities in facial, ear, and foot characteristics in UW-SNV cases were consistent with reports of previously published cases. In the larger sample, spine or chest abnormalities, including pectus excavatum and scoliosis, were reported in 13/25 cases with documented skeletal observations.

**Phenotypic comparisons of DYRK1A to idiopathic ASD**
Rates of microcephaly, intellectual disability, speech delay, motor difficulties, vision impairments, and feeding difficulties were significantly higher in the total DYRK1A group (Pub-SNV, UW-SNV, and Pub-CHR combined) relative both to the full idiopathic SSC comparison cohort and the subset with IQ below 70 (Table 4; Fig. 3).

---

**Table 3 Phenotypic characteristics of DYRK1A**

| Phenotypic characteristic               | Pub-SNV and UW-SNV (n = 42) | Pub-CHR (n = 19) | Total (n = 61) | Sig (Fisher’s exact tests) |
|-----------------------------------------|-------------------------------|-----------------|---------------|---------------------------|
| **N** | **Total** | **%** | **N** | **Total** | **%** | **N** | **Total** | **%** | **Sig** |
| Intellectual disability or Global Developmental Delay | 41 | 42 | 98 | 19 | 19 | 100 | 60 | 61 | 98 | NS |
| Speech delay | 42 | 42 | 100 | 19 | 19 | 100 | 61 | 61 | 100 | NS |
| Motor difficulties | 38 | 38 | 100 | 14 | 15 | 93 | 52 | 53 | 98 | NS |
| Microcephaly | 39 | 42 | 93 | 19 | 19 | 100 | 58 | 61 | 95 | NS |
| Feeding difficulties | 37 | 40 | 93 | 14 | 14 | 100 | 51 | 54 | 94 | NS |
| Vision abnormalities | 26 | 33 | 79 | 8 | 9 | 89 | 34 | 42 | 81 | NS |
| Seizures | 26 | 39 | 67 | 16 | 19 | 84 | 42 | 58 | 72 | NS |
| ASD diagnosis | 16 | 35 | 46 | 2 | 7 | 29 | 18 | 42 | 43 | NS |
| Stereotyped behaviors | 22 | 36 | 61 | 4 | 9 | 44 | 26 | 45 | 58 | NS |
| Anxious behaviors | 11 | 36 | 31 | 1 | 8 | 13 | 12 | 44 | 27 | NS |
| Hyperactive behaviors | 10 | 35 | 29 | 4 | 8 | 50 | 14 | 43 | 33 | NS |
| Behavioral differences | 35 | 42 | 83 | 7 | 19 | 37 | 42 | 61 | 69 | NS |
| 6+ symptoms including ASD | 25 | 42 | 60 | 7 | 19 | 37 | 32 | 61 | 52 | NS |
| 6+ symptoms including broader behavioral difficulties | 32 | 42 | 76 | 10 | 19 | 53 | 42 | 61 | 69 | NS |

Frequency of phenotypic features in cases with disruptive SNVs (Pub-SNV and UW-SNV) to DYRK1A, published chromosomal rearrangements (Pub-CHR) to DYRK1A, and total combined cases. Totals reflect those with complete data. Groups did not significantly differ in gender ratio (Fisher’s exact test) or age (independent sample t test), p > 0.05. Fisher’s exact tests used for group comparisons, Sig significance, NS not significant.
Fig. 2 (See legend on next page.)
The majority of the DYRK1A group (79%) displayed five or more of these phenotypic features in combination. The percentages and group differences remain in the subset of individuals with DYRK1A mutations ascertained for an ASD diagnosis (n = 18, Fig. 3). Co-occurrence of five or more features increased to 89% in those with DYRK1A mutations ascertained for ASD.

Quantitative phenotype of DYRK1A

**DYRK1A vs idiopathic ASD**

Independent sample t tests revealed significant differences between UW-SNV and a matched idiopathic group on measures of head circumference, cognitive ability, and adaptive functioning (Table 5; Fig. 4). The UW-SNV group had significantly smaller head circumference (p < 0.001), significantly lower full-scale IQ (p = 0.002), and significantly lower adaptive abilities (p = 0.001) compared to the idiopathic group. There were no differences between groups on autism symptom severity (ADOS calibrated severity score), age of first words, or age of first independent steps. Outliers across the six phenotypic features of interest represented different UW-SNV individuals, highlighting the variability that is observed when exploring the phenotype quantitatively.

**DYRK1A vs CHD8**

No significant differences were found between CHD8 and idiopathic groups. However, UW-SNV and CHD8 groups differed significantly in head circumference (p < 0.001), such that DYRK1A cases had significantly smaller head size than CHD8 cases. IQ, adaptive functioning, autism symptom severity, age of first words, and age of first steps were similar across groups (Table 5; Fig. 4).

**Contribution of genetic background**

When comparing parental and proband head circumference Z score, the presence of a DYRK1A mutation accounted for a 2.93 SD decrease in head size for probands. Wilcoxon signed rank tests showed that both mothers and fathers exhibited significantly larger head size, controlling for age and gender, compared to their affected child (Z = −2.67, p = 0.008 and Z = −2.20, p = 0.028, respectively (Fig. 5a)). When comparing ASD-related symptoms, DYRK1A accounted for a 5.51 SD increase in SRS total T score (more symptoms). Wilcoxon signed rank tests showed that both mothers and fathers display significantly lower SRS scores compared to their affected child (Z = −3.62, p < 0.001 and Z = −3.41, p = 0.001, respectively (Fig. 5b)). On measures of full-scale IQ, DYRK1A accounted for a 6.09 SD decrease in IQ for probands compared to biparental IQ. Wilcoxon signed rank tests showed that both mothers and fathers display significantly higher IQ compared to their affected child (Z = −2.67, p = 0.008 and Z = −2.20, p = 0.028, respectively (Fig. 5c)).

**Discussion**

This study of the DYRK1A haploinsufficiency phenotype, compiling previously published and newly identified cases, confirms a phenotype characterized by microcephaly, intellectual disability, speech delay, motor difficulties, feeding difficulties, and vision abnormalities. A common facial gestalt included deep-set eyes with a hooded appearance, slightly upslanted palpebral fissures, tubular-shaped nose with pronounced broad tip, high nasal bridge, prominent brow with high anterior hairline, retrognathic jaw, and small chin. Dysmorphic feet, including proximal placement of the first toe, syndactyly of the second and third toe, and unusually long and/or crooked toes, and protruding, post-rotated ears with overfolded, thick helices were also commonly observed. Those with de novo disruptive SNVs and chromosomal rearrangements did not differ in clinical features.

Of those case studies where ASD was mentioned and/or evaluated, 43% of probands received an ASD diagnosis. Among 15 cases who received gold-standard ASD assessment, rates increased to 73%. Additionally, features common to ASD, such as stereotypic and anxious behaviors, were noted in many cases where reference to an ASD diagnosis was absent. This suggests rates of ASD in DYRK1A cohorts may be higher in reality than reported in the total sample of DYRK1A cases published to date.

There are several reasons for the potential underestimated prevalence rate of ASD among published DYRK1A cases. First, most previously published cases relied on medical records, which varied greatly in the
### Table 4: Phenotypic comparisons of DYRK1A to idiopathic ASD

| Phenotypic characteristic | Total DYRK1A sample (n = 61) | DYRK1A ascertained for ASD (n = 18) | SSC idiopathic ascertained for ASD (n = 1981) | Sig (total DYRK1A vs idio total) | SSC Idiopathic ASD with IQ < 70 (n = 487) | Sig (total DYRK1A vs idio IQ < 70) |
|---------------------------|-------------------------------|-------------------------------------|-----------------------------------------------|-----------------|------------------------------------------|------------------------|
|                           | N/total | %       | N/total | %       | N/total | %       | N/total | %       | N/total | %       |
| Intellectual disability or Global Developmental Delay | 60/61 | 98 | 18/18 | 100 | 487/1974 | 25 | p < 0.001 | 487/487 | 100 | – |
| Speech delay               | 61/61 | 100 | 18/18 | 100 | 1173/1981 | 59 | p < 0.001 | 343/487 | 70 | p < 0.001 |
| Motor difficulties         | 52/53 | 98 | 18/18 | 100 | 963/1981 | 49 | p < 0.001 | 253/487 | 52 | p < 0.001 |
| Microcephaly               | 58/61 | 95 | 16/18 | 89 | 31/1958 | 2 | p < 0.001 | 10/485 | 2 | p < 0.001 |
| Feeding difficulties       | 51/56 | 94 | 16/18 | 89 | 386/1981 | 19 | p < 0.001 | 112/487 | 15 | p < 0.001 |
| Vision abnormalities       | 34/42 | 81 | 16/18 | 67 | 355/1981 | 18 | p < 0.001 | 60/487 | 12 | p < 0.001 |
| 5+ symptoms                | 48/61 | 79 | 16/18 | 89 | 6/1981 | 0.30 | – | 5/487 | 1 | – |

Frequency of core phenotypic features (included if reported in 75% or more cases) observed in total DYRK1A sample (Pub-SNV, UW-SNV, and Pub-CHR) compared to frequency of same features in those with DYRK1A mutations ascertained for ASD, a large sample of cases with idiopathic ASD from the Simons Simplex Collection (ascertained for ASD), and a subset of idiopathic cases with IQ < 70. Totals reflect those with complete data. Fisher’s exact tests used to compare total DYRK1A sample to both idiopathic samples on each phenotypic characteristic; all group differences significant, p < 0.001. Sig significance.
detail provided and discussion of comprehensiveness of prior evaluations; as such, it is unknown whether ASD was either evaluated and ruled out, or not evaluated at all. Second, it can be difficult to tease apart symptoms of ASD from those of intellectual disability and speech impairments without specialized training and experience with differential diagnosis within developmental disabilities, particularly in children with complex medical histories. Additionally, establishing an ASD diagnosis may not be the most pressing concern for families (and perhaps providers) given the array of impairments and medical conditions that often accompany children with a DYRK1A mutation. As DYRK1A haploinsufficiency continues to be explored within ASD risk, these factors need to be considered when determining rates in this population.

In an effort to situate the DYRK1A phenotype in the context of ASD, we found the DYRK1A group (Pub-SNV, UW-SNV, Pub-CHR) and DYRK1A sample ascertained for ASD were compared to frequencies of features in idiopathic ASD samples (total and IQ < 70) using Fisher’s exact tests ($p < 0.001$).

**Table 5** Quantitative phenotype and group differences between DYRK1A, idiopathic, and CHD8 groups

| Phenotypic characteristic                  | DYRK1A (UW-SNV) | SSC idiopathic subset | CHD8 | t statistics DYRK1A vs SSC | t statistics DYRK1A vs CHD8 | t statistics CHD8 vs SSC |
|--------------------------------------------|-----------------|-----------------------|------|---------------------------|----------------------------|-------------------------|
| Mean SD N                                  | Mean SD N       | Mean SD N             | t    | d                     | t    | d                     |
| Head circumference Z score                 | −3.62 2.17 10   | 1.21 0.39 10          | 1.76 2.9 11 | 6.94* 3.10 | 6.49** 2.84 | NS –                  |
| Full-scale IQ                              | 45.30 18.14 10  | 81.20 26.12 10        | 60.91 27.39 11 | 3.57* 1.60 | 3.60 1.9 12 | NS –                  |
| Overall adaptive functioning               | 54.80 9.40 10   | 70.50 4.90 10         | 65.00 18.49 12 | 3.81* 1.70 | 3.81 1.7 12 | NS –                  |
| Autism severity (ADOS CSS)                | 6.50 2.80 10    | 7.70 1.25 10          | 8.18 1.78 11 | NS – |NS – |NS –                  |
| Age walked unaided                         | 19.70 6.34 7    | 13.22 2.59 10         | 18.50 4.38 12 | NS – |NS – |NS –                  |
| Age of first single words                  | 45.14 22.82 10  | 17.50 7.92 10         | 25.17 28.01 12 | NS – |NS – |NS –                  |

Descriptives for phenotypic variables commonly impaired in DYRK1A haploinsufficiency for three groups: DYRK1A (n = 10), SSC idiopathic subset randomly samples and matched on age and gender (n = 10), and CHD8 (n = 12). Group comparisons using independent sample t tests between (1) DYRK1A and SSC groups, (2) DYRK1A and CHD8 groups, and (3) CHD8 and SSC groups. *Significant differences between DYRK1A and idiopathic groups, $p < 0.002$; **Significant differences between DYRK1A and CHD8 groups, $p < 0.001$. Independent sample t and Cohen’s d values provided when significant, p value adjusted for multiple comparisons, NS not significant.
SNV, UW-SNV, and Pub-CHR groups combined) exhibited significantly higher incidence of key features compared to those with idiopathic ASD: intellectual disability, speech delay, motor difficulties, vision abnormalities, feeding difficulties, and microcephaly. Frequency of these features also significantly differed between the DYRK1A group and the comparison group with idiopathic ASD and IQ below 70. This is consistent with prior evidence that disruptive SNVs and CNVs often result in significantly more impairing comorbidities than in idiopathic ASD [6, 8]. Notably, when those with DYRK1A mutations who were originally ascertained for an ASD diagnosis were compared to the idiopathic group (also ascertained for ASD), the profile remains the same. This provides further support that the phenotype commonly exhibited in individuals with DYRK1A disruptions and ASD is indeed distinct from idiopathic ASD. The co-occurrence of five or more of these phenotypic features in DYRK1A cases (79% of total sample, 89% of those ascertained for ASD) provides support for further exploration of DYRK1A haploinsufficiency in an individual presenting with concerns of ASD and this combination of phenotypic features.

Prior publications of DYRK1A mutation cases have relied on categorical data to describe clinical phenotype. Our exploration of a quantitative phenotype suggested that DYRK1A haploinsufficiency is differentiable from idiopathic ASD by measures of cognition, adaptive skills, and head size and distinguishable from a different ASD-associated gene mutation, CHD8 by head size. It is possible that further phenotypic differences exist which have not been detected by current diagnostic tools given limits to the level of resolution inherent in clinical assessment. Markers relying on quantitative, brain-based measures may reveal gene-specific profiles. For instance, recent work highlights divergent information processing systems for children with 16p11.2 CNVs [50] and children with an early-emerging disruptive SNV [51]. Considering the intellectual disability associated with DYRK1A haploinsufficiency, a passive, noninvasive neuroimaging approach may help illuminate neuroendophenotypes that link the behavioral phenotype to the underlying neural mechanisms.

Exploring quantitative phenotype in UW-SNV participants illuminated phenotypic heterogeneity among individuals. While DYRK1A mutations significantly impact functioning in a number of domains, the severity of impairment varied among individuals. Family background may, in part, contribute to this variability. While still exploratory, variability in parental phenotype corresponded with variability observed in probands with DYRK1A haploinsufficiency. Most striking were familial patterns on measures of head circumference. Even with the range of microcephaly, probands with the smallest head sizes were related to parents with smaller head sizes compared to other parents within the UW-SNV group. Physiological characteristics are among the most highly correlated between parents and children in typically developing populations, ranging from 0.5 to 0.7 [52, 53]. Our findings suggest that, even in the presence of a de novo, disruptive DYRK1A mutation, parental phenotype may still impact their affected child’s presentation. Of course, secondary genetic events, embryonic or early developmental influences, and treatment must also be considered as potential factors contributing to the variability.

Our findings must be considered in the context of limitations of this study. First, information available for
previously published cases varied widely. While some case reports provided detailed record of psychiatric history, others only included medical history, which also varied in its extensiveness. Full assessment history was unknown for previously published cases, raising questions whether phenotypic features left out of a case report were previously ruled out and confirmed absent or were not assessed. These variations highlight the importance of consistency in phenotypic assessment across future DYRK1A phenotype studies to ensure comprehensive and accurate phenotyping efforts. Second, those with DYRK1A mutations who participated in the same quantitative assessment battery remain small in number. Larger sample sizes are indeed needed to better understand the quantitative phenotype of DYRK1A haploinsufficiency and potential variability between affected individuals. Also, while comparison of DYRK1A mutation cases to idiopathic ASD provides important confirmation of distinct comorbidities within ASD, it is important to acknowledge that individuals in the idiopathic group may, with future advances in our understanding of the genetics of ASD, no longer be identified as idiopathic. The idiopathic group analyzed in this study likely represents a population with fewer syndromic features than populations with ASD and other genetic events. Thus, further studies and larger samples of other ASD-associated gene mutations are needed to further distinguish how the DYRK1A haploinsufficiency phenotype differs from that of other disruptive gene events. Future studies of this population should also aim for greater specificity in phenotypic characterization in efforts to better understand DYRK1A haploinsufficiency as a unique clinical profile. Continued study of ASD-associated genes, including DYRK1A, will allow for improved understanding of ASD subtypes and inform future approaches to personalized treatment.
Conclusions

DYRK1A haploinsufficiency results in a clinical phenotype which includes microcephaly, intellectual impairment, the presence of vision and motor difficulties, feeding difficulties, language delays, and ASD risk. The DYRK1A profile suggests a potential subtype of ASD. Despite a consistent profile, quantitative assessment highlights heterogeneity in the severity of impairments, with parental phenotype, reflecting genetic background, as a likely contributor to that variability among individuals.

Additional files

Additional file 1: Variant information for known de novo DYRK1A mutation cases. Full variant information for previously published DYRK1A variants and patients seen at UW. Previously published cases identified by first author last name and UW cases denoted TXXX. Sheets organized by variant type: snv/indels, cnvs, mosaic variants, and translocations/ inversions. (XLSX 17 kb)

Additional file 2: Variant locations via UCSC Genome Browser. Presentation of DYRK1A isomeric variants and locations for previously published and UW cases. Figure generated in UCSC Genome Browser [54]. (PDF 201 kb)

Abbreviations

ASD: Autism spectrum disorder; CHR: Chromosomal rearrangement (including CNVs, translocations, and inversions); CNV: Copy number variation; Pub-CHR: Previously published chromosomal rearrangements; Pub-SNV: Previously published disruptive SNVs; SNV: Single nucleotide variant (disruptive variants include nonsense, frameshift, splice site, and missense mutations); UW-SNV: UW study participants with disruptive SNVs to DYRK1A

Acknowledgements

We would like to thank our funding sources and the families who took part in this study.

Funding

This research was supported by the National Institute for Mental Health, #R01MH100047 to R.A.B. and #R01MH101221 to E.E.E. E.E.E. is an investigator of the Howard Hughes Medical Institute.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

RAB and EEE developed the study concept. EEE and TT performed genetic contributions. RKE, HCM, and JG. RKE drafted the manuscript, and RAB, TT, JG, CMH, and EEE provided critical revisions. All authors approved the final version of the manuscript for submission.

Ethics approval and consent to participate

Written informed consent was obtained from the participants for publication of their individual details and accompanying images in this manuscript. The consent form is held by the authors and is available for review by the Editor-in-Chief.

Consent for publication

Written informed consent was obtained from the participants for publication of their individual details and accompanying images in this manuscript. The consent form is held by the authors and is available for review by the Editor-in-Chief.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Psychiatry and Behavioral Sciences, University of Washington, CHDD Box 357920, Seattle, WA 98195, USA. 2Department of Genome Sciences, University of Washington, Seattle, WA, USA. 3School of Medicine, University of Washington, Seattle, WA, USA. 4Howard Hughes Medical Institute, Seattle, WA, USA. 5Center on Human Development and Disability, University of Washington, Seattle, WA, USA.

Received: 30 June 2017 Accepted: 27 September 2017
Published online: 05 October 2017

References

1. King BH, Navot N, Bernier R, Webb SJ. Update on diagnostic classification in autism. Current opinion in psychiatry. 2014;27(2):105–9. doi:10.1097/yco.0000000000000040. Pubmed 24441420
2. Lord C, Petkova E, Hus V, Gan W, Lu F, Martin DM, et al. A multisite study of the clinical diagnosis of different autism spectrum disorders: Arch Gen Psychiatry. 2012;69(5):305–13. doi:10.1001/archgenpsychiatry.2011.148. Pubmed 2011/11/09. Pubmed PMID: 22065253; Pubmed Central PMCID: PMCPMC3626112
3. Higdon R, Earl RK, Stanberry L, Hudac CM, Montague E, Stewart E, et al. The promise of multi-omics and clinical data integration to identify and target personalized healthcare approaches in autism spectrum disorders. Omiacs : a journal of integrative biology. 2015;10(6):197–208. doi:10.1089/omi.2015.0020. Pubmed 2015/05/02. Pubmed PMID: 25831069; Pubmed Central PMCID: PMCPMC4388910
4. Jeste SS, Geschwind DH. Disentangling the heterogeneity of autism spectrum disorder through genetic findings. Nat Rev Neuro. 2014;10(2):74–81. doi:10.1038/nrneuro.2013.278. Pubmed 2014/01/29. Pubmed PMID: 24686882; Pubmed Central PMCID: PMCPMC4125617
5. O’Roak BJ, Derzotsis P, Lee C, Vives L, Schwartz JJ, Girirajan S, et al. Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet. 2011;43(6):585–9. doi:10.1038/ng.835. Pubmed 2011/05/17. Pubmed PMID: 21572417; Pubmed Central PMCID: PMCPMC3115696
6. lossifov I, O’Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515(7526):216–21. doi:10.1038/nature13908. Pubmed 2014/11/05. Pubmed PMID: 25363768; Pubmed Central PMCID: PMCPMC4313871
7. Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010;466(7304):638–72. doi:10.1038/nature09146. Pubmed 2010/06/10. Pubmed PMID: 20531469; Pubmed Central PMCID: PMCPMC3021798
8. Sanders SJ, He X, Willsey AJ, Ercan-Sencicek AG, Samocha KE, Cicci A, et al. Insights into autism spectrum disorder genomic architecture and biology from 71 risk loci. Neuron. 2015;87(6):1215–33. doi:10.1016/j.neuron.2015.09.016. Pubmed 2015/09/25. Pubmed PMID: 26402605; Pubmed Central PMCID: PMCPMC4262467
9. Vostman IA, Staal WG, van Daalen E, van Engeland H, Hochstenbach PF, Franke L. Identification of novel autism candidate regions through analysis of reported cytogenetic abnormalities associated with autism. Mol Psychiatry. 2006;11(1):1, 18-28. Epub 2005/10/06. Pubmed PMID: 16205736. doi:10.1038/yco.2005.171
10. Stessman HA, Bernier R, Eichler EE. A genotype-first approach to defining the subtypes of a complex disease. Cell. 2014;156(5):827–72. https://doi.org/10.1016/j.cell.2014.05.001. Pubmed 2014/05/15. Pubmed PMID: 24581488; Pubmed Central PMCID: PMCPMC4076166
11. Bernier R, Golzio C, Xiong B, Stessman HA, Coe BP, Penn O, et al. Disruptive CHD8 mutations define a subtype of autism early in development. Cell. 2014;158(2):263–76. doi:10.1016/j.cell.2014.06.017. Pubmed 2014/07/08. Pubmed PMID: 24998929; Pubmed Central PMCID: PMCPMC4136921
12. Hetemondert C, Vulto-van Silfhout AT, Coe BP, Vandeveneyer G, Rooms L, van den Ende J, et al. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. Nat Genet. 2014;46(4):380–4. doi:10.1038/ng.2899. Pubmed 2014/02/18. Pubmed PMID: 24531329; Pubmed Central PMCID: PMCPMC3990853
13. van Bon BW, Coe BP, Bernier R, Green C, Gerds J, Witherspoon K, et al. Disruptive de novo mutations of DYRK1A lead to a syndromic form of
autism and ID. Mol Psychiatry. 2016;21(1):26–32. doi:10.1038/mp.2015.5.
Epub 2015/02/25. PubMed PMID: 25707938; PubMed Central PMCID: PMCPMC4547916

14. O’Roak BJ, Vives L, Fu W, Egertson JD, Stanaway IB, Phelps IG, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science (New York, NY). 2012;338(6114):1619–22. doi:10.1126/science.1227764. Epub 2012/11/20. PubMed PMID: 23160955; PubMed Central PMCID: PMC3528801

15. Bronnick LM, Redin C, Dranet S, Piton A, Lyons M, Passemard S, et al. Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A. European journal of human genetics : EJHG. 2015;23(11):1482–7. doi:10.1038/ejhg.2015.29. Epub 2015/04/30. PubMed PMID: 25920557; PubMed Central PMCID: PMCPMC4613470

16. APA. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, D.C. Author; 2013.

17. van Bon BW, Ciccolin C, BBA dv. In: Pagon RA, Adam MP, Ardiing HH, editors. DYRK1A-related intellectual disability syndrome. Seattle: University of Washington; 2015.

18. Tejedor F, Zhu XR, Kaltenbach E, Ackermann A, Baumann A, Canal I, et al. A new protein kinase family involved in postembryonic neurogenesis in Drosophila. Neuron. 1995;14(2):287–301. Epub 1995/02/01. PubMed PMID: 7857639

19. Focut V, Dierssen M, Alcantara S, Martínez S, Martí E, Casas C, et al. DYRK1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol Cell Biol. 2002;22(18):6366–74. Epub 2002/08/23. PubMed PMID: 12192061; PubMed Central PMCID: PMCPMC1536539

20. Focut V, Martínez De Llagran M, Estivill X, Arbones M, Dierssen M. Haploinsufficiency of Dyrk1A in mice leads to specific alterations in the development and regulation of motor behavior. Behav Neurosci. 2004;118(4): 815–21. doi:10.1037/0735-7044.118.4.815. Epub 2004/08/11. PubMed PMID: 15301607

21. Ji, J, Lee H, Argiropoulos B, Ackermann B, Appel NL, et al. Molecular and genetic basis of Down syndrome critical region (21q22). Mol Cell. 2006;24(5):525–40. doi:10.1016/j.molcel.2006.07.007. Epub 2006/08/16. PubMed PMID: 16923131; PubMed Central PMCID: PMCPMC662882

22. Lucu SM, Pohl D, Seif E, Wagner JD, Dyment DA, Dacoud H. Case report of novel DYRK1A mutations in 2 individuals with syndromic intellectual disability and a review of the literature. BMC medical genetics. 2016;17:15. doi:10.1186/s12881-016-0276-4. Epub 2016/02/29. PubMed PMID: 26922654; PubMed Central PMCID: PMCPMC4944818

23. Möller R, Kubart S, Hoefenlein M, Heye B, Vogel I, Hansen CP, et al. Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly. Am J Hum Genet. 2008;83(5):1165–70. doi:10.1016/j.ajhg.2008.03.001. Epub 2008/04/15. PubMed PMID: 18405873; PubMed Central PMCID: PMCPMC2427221

24. van Bon BW, Hoischen A, Hehir-Kwa J, de Brouwer AP, Ruivenkamp C, Gijbers AC, et al. Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly. Clin Genet. 2011;79(3):296–9. doi:10.1111/j.1399-0004.2010.01544.x. Epub 2011/02/08. PubMed PMID: 21294719

25. Fraser FC, Sadownik AD. Correlation of IQ in subjects with Down syndrome and their parents and sibs. J Ment Defic Res. 1976;20(3):179–82. Epub 1976/09/01. PubMed PMID: 135090

26. Malich S, Lango RH, Schinzel A, Molinari L, Eliholzer U. Phenotypic heterogeneity of growth and psychometric intelligence in Prader-Willi syndrome: variable expression of a contiguous gene syndrome or parent-child resemblance? Am J Med Genet. 2000;90(4):298–304. Epub 2000/04/15. PubMed PMID: 10766887

27. Moreno-DeLuca A, Evans DW, Boomier KB, Hanson E, Bernier R, Goin-Kochel RP, et al. The role of parent cellular, behavioral, and motor profiles in clinical variability in individuals with chromosome 16p11.2 deletions. JAMA psychiatry. 2015;72(2):119–26. doi:10.1001/jamapsychiatry.2014.2147. Epub 2014/12/21. PubMed PMID: 25499322

28. Breeze MA. The genetic contribution to stature. Horm Res. 1996;45(Suppl 2):56–8. Epub 1996/01/01. PubMed PMID: 8805046

29. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, Foster B. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45(6):580–8. doi:10.1038/ng.2653.
report Surveillance summaries (Washington, DC : 2002). 2016;65(3):1–23. 10.15585/mmwr.ss6503a1. Epub 2016/04/01. PubMed PMID: 27031587

50. Hudac CM, Kresse A, Aaronson B, DesChamps TD, Webb SJ, Bernier RA, et al. Modulation of mu attenuation to social stimuli in children and adults with 16p11.2 deletions and duplications exploring the heterogeneity of neural social indices for genetically distinct etiologies of autism. (1866–1947 (Print)). D - NLM: PMC4514956 OTO - NOTNL.

51. Hudac CM, Stessman HAF, DesChamps TD, Kresse A, Faja S, Neuhaus E, et al. Exploring the heterogeneity of neural social indices for genetically distinct etiologies of autism. (1866–1947 (Print)).

52. Clark PJ. The heritability of certain anthropometric characters as ascertained from measurements of twins. 1955(0002–9297 (Print)). D - CLML: 5630:10388 D - NLM: PMC1716621 OTO - NLM.

53. Weaver DD, Christian JC. Familial variation of head size and adjustment for parental head circumference. J Pediatr. 1980;96(6):990–4. doi:10.1016/S0022-3476(80)80623-8

54. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. Genome Res. 2002;12(6):996–1006.